Skip to main content
. 2010;12(2):PCC.09m00799. doi: 10.4088/PCC.09m00799gry

Figure 5.

Figure 5

Proportion of Patients in Each Treatment Group With Drug-Emergent Neuromotor Syndromes

aP = .001; haloperidol and risperidone vs olanzapine.

bP = .013; haloperidol vs risperidone and olanzapine.

cP = .014; haloperidol vs risperidone and olanzapine.